Tenderwize
Retour à la recherche

Open house Denosumab discount agreements

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline May 05, 2027 · 249 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Denosumab, ATC M05BX04

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value is provided, making it impossible to assess financial attractiveness.

Agreements automatically terminate if a formal discount contract for the same substance comes into effect. This could s...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Supply of Denosumab (active substance, ATC M05BX04) under discount agreements.
  • Non-exclusive framework agreement with no guarantee of volume or exclusivity.
Afficher le résumé complet

This is an open house model (non-exclusive) for discount agreements on the drug Denosumab (ATC M05BX04) with AOK Bayern. It is not a standard procurement procedure; any eligible pharmaceutical company can join under identical non-negotiable terms. Agreements run from 01/07/2025 to 30/06/2027, with rolling entry until 05/05/2027. No estimated value provided. Submission requires a signed contract and self-declaration of reliability, either in paper form (two copies) or electronically with a qualified electronic signature. Eligibility is limited to pharmaceutical companies.

Risques

No estimated value is provided, making it impossible to assess financial attractiveness.

Agreements automatically terminate if a formal discount contract for the same substance comes into effect. This could s...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Proof of legal representation (handelsregister extract or power of attorney).

Eligibility

  • Eligible participants: only pharmaceutical companies.

Administrative

  • Submission of a signed contract and a signed self-declaration of reliability.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria; all eligible companies are accepted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house Denosumab discount agreements

Non-exclusive discount agreements for Denosumab (ATC M05BX04) to be concluded with all eligible pharmaceutical companies under identical terms. Place of performance: Bavaria, Germany (DE212). Framework agreement type.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Jun 2025 - Jun 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; all eligible companies are accepted.

Date limite

Deadline May 05, 2027

Détails de la procédure

Date de publication
15 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
317417-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30